CardioDx Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the presentation of the study, "The Use of a Gene Expression Score Showed Clinical Utility in Evaluating African Americans Presenting with Symptoms Suggestive of Obstructive Coronary Artery Disease in a Primary Care Practice," at the 36th annual North American Meeting of the Society for Medical Decision Making, taking place from Oct. 18-22 in Miami.

A research study published in the July issue of the Journal of the American College of Cardiology reports that genetic mutations in a neuronal sodium channel gene are associated with inherited sudden cardiac death syndromes, including the Brugada syndrome. The study, performed at the Cardiac Research Institute at Masonic Medical Research Laboratory (MMRL) in Utica, N.Y., included physicians and scientists from throughout the world who referred patients with life-threatening cardiac arrhythmias to the MMRL for genetic screening.

Infinitt North America will be featuring Dose M 2.0 radiation dose tracking software at this year’s RSNA in Chicago. The new version expands the capture of dose data from multiple-modalities and can be integrated with radiology information systems (RIS), picture archive and communication systems (PACS) or electronic medical records (EMRs) to make dose information accessible as part of the patient record.

Calgary Scientific Inc. has gained U.S. Food and Drug Administration (FDA) clearance of ResolutionMD 4.0 diagnostic medical imaging software for all modalities and China Food and Drug Administration (CFDA) certification for diagnosis on mobile devices in China.

Siemens Healthcare has announced that the U.S. Food and Drug Administration (FDA) has cleared the new Prime edition of its Acuson SC2000 premium cardiovascular imaging system — a system that offers live full-volume color Doppler imaging of heart valve anatomy and blood flow using a new true volume transesophageal echo (TEE) probe.

Cardiac Stress Testing Imaging Reduce Health Costs Improve Patient Outcomes

In a new study recently published in the Annals of Internal Medicine, researchers at NYU Langone Medical Center concluded that overuse of cardiac stress testing with imaging has led to rising healthcare costs and unnecessary radiation exposure to patients.

 

October 20, 2014 — Boston Scientific Corp. has initiated the PLATINUM Diversity trial to evaluate the clinical performance of the Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System in underserved patient populations, including women and people of color. The Promus Premier stent system is the company's latest durable polymer drug-eluting stent (DES) and is approved by the U.S. Food and Drug Administration (FDA) to treat coronary artery disease. Wayne Batchelor, M.D., FACC, FSCAI, and co-principal investigator, enrolled the first patient in the PLATINUM Diversity trial at Tallahassee Memorial Hospital, in Tallahassee, Fla.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now